Caraco settles with US FDA on GMP violations
This article was originally published in Scrip
Caraco Pharmaceutical Laboratories has entered into a consent agreement with the US FDA that bars the company from re-starting generic drug manufacturing operations at its facilities in the Detroit, Michigan, area until they comply with good manufacturing practices (GMPs).
You may also be interested in...
Chronicle of the development and review of Sarepta’s golodirsen for treatment of Duchenne muscular dystrophy patients with a genetic mutation amenable to exon 53 skipping.
ODE I director Ellis Unger chafed at the notion of approving the Duchenne muscular dystrophy drug golodirsen on the same unvalidated surrogate marker, this time in the face of infection and renal toxicity concerns; OND’s Peter Stein granted Sarepta’s appeal while also calling attention to the company’s failure to timely conduct the eteplirsen confirmatory trial.
Advisory committee votes 24-2 against approval of Intellipharmaceutics’ Aximris XR due to concerns the extended-release oxycodone formulation may be more susceptible to intranasal abuse than existing products; Esteve fares better with its tramadol/celecoxib combination, securing a tie vote on approval for acute pain.